Skip to content
Back to news

Autoimmune Diseases: first option within global license agreement exercised for clinical development of OSE-127

Press Release :

Servier and OSE Immunotherapeutics* announced the first step under a two-step option agreement for exclusive global rights to OSE-127.

OSE-127 is a differentiated monoclonal antibody antagonist targeting the interleukin-7 receptor (IL-7R), discovered by OSE, for the treatment of auto-immune diseases and chronic inflammation.

Under the license agreement, exercising the first step of the option triggered a €10 million milestone payment to OSE from Servier, who made the decision following the achievement of prespecified data-based developmental achievements. OSE-127 is currently being evaluated in a Phase 1 clinical trial in which the first healthy volunteers were enrolled and dosed in December 2018.

“The partnership with OSE Immunotherapeutics illustrates Servier’s resolve to provide innovative therapeutic solutions for patients with immune-inflammatory diseases. It fits with Servier’s philosophy of focusing its research on diseases with high unmet needs, by relying on partners with complementary knowledge and technologies to accelerate research for the benefit of patients,” declared Philippe Moingeon, Head of therapeutic area immuno-inflammatory diseases at Servier.

OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.

*OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and auto-immune diseases.


Contacts :

OSE Immunotherapeutics
Sylvie Détry
+33 143 297 857

U.S. Media: LifeSci Public Relations
Darren Opland, Ph.D.
+1 646 627 8387